Vestal Point Capital’s Damora Therapeutics DMRA Stock Holding History

Vestal Point Capital’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15M	Sell	575,000 -25,000	-4%	-$605K	0.35%	47
2026 Q1	$15.5M	Buy	+600,000	New	+$15.4M	0.43%	57

Other funds holding DMRA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCP

Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

Vestal Point Capital's DMRA Position: Q2 2026 in Review

Vestal Point Capital reduced its Damora Therapeutics (DMRA) stake by 4.2% in Q2 2026, selling an estimated $605K and leaving 575,000 shares worth $15M. The position accounts for 0.35% of the portfolio, ranked #47.

Vestal Point Capital first reported a position in DMRA in Q1 2026 and has held it in 2 quarters since. The position peaked at $15.5M in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

Vestal Point Capital held 575,000 shares of Damora Therapeutics worth $15M as of Q2 2026.
Vestal Point Capital sold 25,000 Damora Therapeutics shares in Q2 2026, an estimated $605K.
Damora Therapeutics made up 0.35% of Vestal Point Capital's portfolio in Q2 2026, its #47 holding.
Vestal Point Capital first reported a position in Damora Therapeutics in Q1 2026 and has held it in 2 quarters since.
Vestal Point Capital's Damora Therapeutics position peaked at $15.5M in Q1 2026.
104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.